drugset

drugset / Trial / NCT01625559

Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)

NCT01625559 ↗

Phase 1 Completed 3 enrolled CHABiotech CO., Ltd

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of RPE cellular therapy in patients with SMD

Timeline

Start: 2012-09
Primary completion: 2015-04
Completion: 2015-04

Publications

Sung Y, Lee MJ, Choi J, Jung SY, Chong SY, Sung JH, Shim SH, Song WK. Long-term safety and tolerability of subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium in Asian Stargardt disease patients. Br J Ophthalmol. 2021 Jun;105(6):829-837. doi: 10.1136/bjophthalmol-2020-316225. Epub 2020 Jul 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MA09-hRPE	Cell therapy	—	Other

Indications